BeStock  
Stocks › Biotechnology › NRIX

Nurix Therapeutics NRIX

US equityMarket cap rank #2921Biotechnology
$12.85 −$0.75 (-5.51%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.85 0.00%
Open$13.40
Prev close$13.60
Day range$12.83 – $13.67
Volume2.43M
Market cap$1.40B
P/E (TTM)5.3
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Aug 2026

Revenue$673.06M+8,426.3% YoY
Operating profit$559.45M+712.2% YoY
Net profit$549.81M+736.2% YoY
Diluted EPS$4.73+559.2% YoY
Free cash flow$614.24M+1,122.1% YoY
Operating cash flow$615.63M

Revenue, last 8 quarters

$13.3MNov '24$18.5MFeb '25$44.1MMay '25$7.9MAug '25$13.6MNov '25$6.3MFeb '26$9.0MMay '26$673.1MAug '26

Net profit, last 8 quarters

$-58.5MNov '24$-56.4MFeb '25$-43.5MMay '25$-86.4MAug '25$-78.2MNov '25$-87.2MFeb '26$-89.5MMay '26$549.8MAug '26

Diluted EPS by quarter

-0.75Nov '24-0.67Feb '25-0.52May '25-1.03Aug '25-0.82Nov '25-0.79Feb '26-0.81May '264.73Aug '26

Free cash flow by quarter

$-50.9MNov '24$-64.6MFeb '25$-65.8MMay '25$-60.1MAug '25$-73.0MNov '25$-73.0MFeb '26$-98.5MMay '26$614.2MAug '26

Annual revenue

$17.8MFY20$29.8MFY21$38.6MFY22$77.0MFY23$54.5MFY24$84.0MFY25

Profitability & balance sheet

Operating margin41.3%
Net margin42.0%
Return on equity44.0%
Return on assets34.3%
Return on invested capital37.9%
Current ratio8.44
Liabilities / assets19.0%
Cash & investments$1.05B
Total debt$62.09M
Net cash (debt)$986.16M
Free cash flow / sales52.7%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $673.06M $9.04M $6.25M $83.98M $13.58M
Total Operating Revenue $673.06M $9.04M $6.25M $83.98M $13.58M
Operating Expense $113.61M $103.25M $98.75M $369.65M $96.67M
Selling and Admin Expenses $34.35M $15.59M $14.61M $52.74M $13.65M
-General & Admin Expense $34.35M $15.59M $14.61M $52.74M $13.65M
Research & Development $79.26M $87.65M $84.14M $316.90M $83.02M
Operating Profit $559.45M -$94.20M -$92.50M -$285.67M -$83.10M
Net Non-Operating Interest Income (Expense) $3.96M $4.40M $5.32M $21.97M $4.87M
Non-Operating Interest Income $3.96M $4.40M $5.32M $21.97M $4.87M
Pretax Profit $563.41M -$89.81M -$87.17M -$263.70M -$78.22M
Tax $13.61M -$271,000.00 – $760,000.00 $0.00
Net Profit $549.81M -$89.54M -$87.17M -$264.46M -$78.22M
Profit from Continuing Operations $549.81M -$89.54M -$87.17M -$264.46M -$78.22M
Net Income to Parent Company $549.81M -$89.54M -$87.17M -$264.46M -$78.22M
Net Income to Common Stockholders $549.81M -$89.54M -$87.17M -$264.46M -$78.22M
Basic EPS $4.93 -$0.81 -$0.79 -$3.05 -$0.82
Diluted EPS $4.73 -$0.81 -$0.79 -$3.05 -$0.82

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.20B $535.54M $636.13M $688.14M $688.14M
Total Current Assets $1.10B $456.48M $554.39M $606.82M $606.82M
Cash and Cash Equivalents & Short-Term Investments $1.05B $443.53M $540.73M $592.94M $592.94M
-Cash and Cash Equivalents $720.24M $67.69M $71.20M $246.96M $246.96M
-Short Term Investments $328.01M $375.84M $469.54M $345.98M $345.98M
Receivables $20.00M – – – –
-Accounts Receivable $20.00M – – – –
Other Current Assets $35.44M $12.95M $13.66M $13.88M $13.88M
Total Non-Current Assets $91.61M $79.06M $81.74M $81.32M $81.32M
Net PPE $68.04M $70.11M $73.35M $73.01M $73.01M
-Gross PPE $111.51M $111.46M $113.08M $110.79M $110.79M
-Accumulated Depreciation -$43.47M -$41.34M -$39.72M -$37.78M -$37.78M
Investments and Advances $14.83M – – – –
-Available for Sale Securities $14.83M – – – –
Other Non-Current Assets $8.74M $8.95M $8.38M $8.31M $8.31M
Total Liabilities $226.99M $132.91M $155.24M $149.39M $149.39M
Total Current Liabilities $130.74M $72.02M $92.20M $86.47M $86.47M
Payables $46.93M $12.46M $11.33M $12.27M $12.27M
-Accounts Payable $32.98M $12.21M $10.29M $11.22M $11.22M
-Total Tax Payable $13.95M $247,000.00 $1.04M $1.06M $1.06M
Current Accrued Expenses $27.98M $28.27M $31.12M $30.16M $30.16M
Short-Term Debt and Capital Lease Obligation $3.24M $3.22M $3.20M $2.82M $2.82M
-Current Capital Lease Obligation $3.24M $3.22M $3.20M $2.82M $2.82M
Current Deferred Liabilities $30.84M $13.32M $18.75M $17.58M $17.58M
Other Current Liabilities $1.49M $1.30M $1.93M $2.10M $2.10M
Total Non-Current Liabilities $96.25M $60.89M $63.04M $62.92M $62.92M
Long Term Debt and Capital Lease Obligation $62.09M $54.92M $55.45M $52.91M $52.91M
-Long Term Capital Lease Obligation $62.09M $54.92M $55.45M $52.91M $52.91M
Non-Current Deferred Liabilities $34.15M $5.97M $7.59M $10.01M $10.01M
Total Equity $968.31M $402.63M $480.89M $538.75M $538.75M
Stockholders' Equity $968.31M $402.63M $480.89M $538.75M $538.75M
Capital Stock $109,000.00 $104,000.00 $103,000.00 $102,000.00 $102,000.00
-Common Stock $109,000.00 $104,000.00 $103,000.00 $102,000.00 $102,000.00
-Preferred Stock $0.00 $0.00 – $0.00 $0.00
Additional Paid-In Capital $1.60B $1.58B $1.57B $1.54B $1.54B
Retained Earnings -$630.13M -$1.18B -$1.09B -$1.00B -$1.00B
Gains/Losses Not Affecting Retained Earnings -$210,000.00 -$145,000.00 $56,000.00 $105,000.00 $105,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $615.63M -$96.57M -$71.91M -$249.47M -$67.83M
Net cash flow from continuing operations $615.63M -$96.57M -$71.91M -$249.47M -$67.83M
Net Income from Continuing Operations $549.81M -$89.54M -$87.17M -$264.46M -$78.22M
Gain/Loss from Continuing Operations $0.00 $0.00 $160,000.00 $89,000.00 –
Depreciation & Depletion & Amortization $3.62M $3.85M $3.78M $18.86M $4.63M
Change in Working Capital $52.37M -$20.72M $3.90M -$31.60M -$1.55M
-Change in Receivables -$20.00M – – – –
-Change in Prepaid Assets -$13.56M $263,000.00 $1.29M -$6.23M -$1.28M
-Change in Payables and Accrued Expense $41.04M -$13.38M $3.66M $16.68M $14.07M
-Change in Other Current Liabilities -$809,000.00 -$557,000.00 $205,000.00 -$5.07M -$756,000.00
-Change In Other Working Capital $45.70M -$7.04M -$1.25M -$36.98M -$13.58M
Net cash flow from investing $31.58M $93.00M -$123.83M $147.85M $346,000.00
Net Cash Flow from Continuing Investing Activities $31.58M $93.00M -$123.83M $147.85M $346,000.00
Net PPE Purchase and Sale -$1.39M -$1.94M -$1.05M -$14.00M -$5.13M
Net Investment Purchase and Sale $32.97M $94.93M -$122.78M $161.86M $5.48M
Financing Cash Flow $5.16M $66,000.00 $19.98M $238.64M $236.01M
Net Cash Flow from Continuing Financing Activities $5.16M $66,000.00 $19.98M $238.64M $236.01M
Net Common Stock Issuance $0.00 $0.00 $18.00M $234.76M $234.76M
Proceeds from Stock Option Exercised $5.16M $66,000.00 $1.97M $3.88M $1.25M
Ending Cash Balance $721.02M $68.65M $72.16M $247.93M $247.93M
Net Change in Cash $652.37M -$3.51M -$175.77M $137.03M $168.52M
Beginning Cash Balance $68.65M $72.16M $247.93M $110.90M $79.41M
Free Cash Flow $614.24M -$98.51M -$72.96M -$263.47M -$72.96M

Discussion

No comments yet — be the first to weigh in on NRIX.

Sign in to join the discussion.

Scroll to Top